1. Roffi M, Patrono C, Collet J-P et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. EHJ 2015. doi: 10.1093/eurheartj/ehv320
2. Mangano DT. Perioperative cardiac morbidity. Anesthesiology 1990; 72: 153–84.
3. Mangano DT. Perioperative cardiovascular morbidity: new developments. Best Pract Res Clin Anaesthesiol 1999; 13 (3): 335–48.
4. Vicenzi MN, Meislitzer T, Heitzinger B et al. Coronary artery stenting and non-cardiac surgery – a prospective outcome study. Br J Anaesth 2006; 96: 686–93.
5. Iakovou I, Schmidt T, Bonizzoni E et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. J Am Med Assoc 2005; 293: 2126–30.
6. Patrono C, Baigent C, Hirsh J et al. Аntiplatelet Drugs. Chest 2008; 133 (6 Suppl.): 199S–233S.
7. Awtry EH, Loscalzo J. Aspirin. Circulation 2000; 101: 1206–18.
8. Jimenez AH, Stubbs ME, Tofler GH et al. Rapidity and duration of platelet suppression by entericcoated aspirin in healthy young men. Am J Cardiol 1992; 69: 258–62.
9. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86.
10. Hall R, Mazer CD. Antiplatelet drugs: a review of their pharmacology and management in the perioperative period. Anesth Analg 2011; 112: 292–318.
11. Collaborative overview of randomised trials of antiplatelet therapy – I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. BMJ 1994; 308: 81–106.
12. Baigent C, Blackwell L, Collins R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849–60.
13. Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). EHJ 2012; 33: 1635–701.
14. Amsterdam EA, Wenger NK, Brindis RG et al. 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes. Circulation 2014; 130: e344–e426.
15. O’Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. Circulation 2013; 127: e362–e425.
16. Fihn SD, Gardin JM, Abrams J et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. JACC 2012; 60 (24): e44–e164.
17. Brott TG, Halperin JL, Abbara S et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease. Circulation 2011; 124: e54–e130.
18. Rooke TW, Hirsch AT, Misra S et al. 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (Updating the 2005 Guideline). Circulation 2011; 124: 2020–45.
19. Burger W, Chemnitius JM, Kneissl GD et al. Low-dose aspirin for secondary cardiovascular prevention – cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation – review and meta-analysis. J Intern Med 2005; 257: 399–414.
20. Palmer JD, Sparrow OC, Iannotti F. Postoperative hematoma: a 5-year survey and identification of avoidable risk factors. Neurosurgery 1994; 35: 1061–4.
21. Oscarsson A, Gupta A, Fredrikson M et al. To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial. Br J Anaesth 2010; 104: 305–12.
22. Kaluza GL, Joseph J, Lee JR et al. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. JACC 2000; 35: 1288–94.
23. Sharma AK, Ajani AE, Hamwi SM et al. Major noncardiac surgery following coronary stenting: when is it safe to operate? Catheter Cardiovasc Interv 2004; 63: 141–5.
24. Biondi-Zoccai GG, Lotrionte M, Agostoni P et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. EHJ 2006; 27: 2667–74.
25. Collet JP, Himbert F, Steg PG. Myocardial infarction after aspirin cessation in stable coronary artery disease patients. Int J Cardiol 2000; 76: 257–8.
26. Collet JP, Montalescot G, Balnchet B et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation 2004; 110: 2361–7.
27. Ferrari E, Benhamou M, Cerboni P et al. Coronary syndromes following aspirin withdrawal, a special risk for late stent thrombosis. JACC 2005; 45: 456–9.
28. Maulaz AB, Bezerra DC, Michel P, Bogousslavsky J. Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch Neurol 2005; 62 (8): 1217–20.
29. Sung JJ, Lau JY, Ching JY et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med 2010; 152: 1–9.
30. Madan GA, Madan SG, Madan G et al. Minor oral surgery without stopping daily low-dose aspirin therapy: a study of 51 patients. J Oral Maxillofac Surg 2005; 63: 1262–5.
31. Chu MB, Turner RB, Kriegel DA. Patients with drug-eluting stents and management of their anticoagulant therapy in cutaneous surgery. J Am Acad Dermatol 2011; 64: 553–8.
32. Alcalay J, Alkalay R. Controversies in perioperative management of blood thinners in dermatologic surgery: continue or discontinue? Dermatol Surg 2004; 30: 1091–4.
33. Cook-Norris RH, Michaels JD, Weaver AL et al. Complications of cutaneous surgery in patients taking clopidogrel-containing anticoagulation. J Am Acad Dermatol 2011; 65: 584–91.
34. Douketis JD, Spyropoulos AC, Spencer FA et al. Perioperative Management of Antithrombotic Therapy. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST 2012; 141 (2 Suppl.): e326S–e350S.
35. Manocha D, Singh M, Mehta N et al. Bleeding Risk after Invasive Procedures in Aspirin/NSAID Users: Polypectomy Study in Veterans. Am J Med 2012; 125: 1222–7.
36. Yousfi M, Gostout CJ, Baron TH et al. Postpolypectomy lower gastrointestinal bleeding: potential role of aspirin. Am J Gastroenterol 2004; 99: 1785–9.
37. Hui AJ, Wong RM, Ching JY et al. Risk of colonoscopic polypectomy bleeding with anticoagulants and antiplatelet agents: analysis of 1657 cases. Gastrointest Endosc 2004; 59: 44–8.
38. Anderson MA, Ben-Menachem T, Gan SI et al. Management of antithrombotic agents for endoscopic procedures. Gastrointest Endosc 2009; 70: 1060–70.
39. Lindblad B, Persson NH, Takolander R et al. Does low-dose acetylsalicylic acid prevent stroke after carotid surgery? A double blind, placebo-controlled randomized trial. Stroke 1993; 24: 1125–8.
40. Neilipovitz DT, Bryson GL, Nichol G. The effect of perioperative aspirin therapy in peripheral vascular surgery: a decision analysis. Anesth Analg 2001; 93: 573–80.
41. Rosenbaum A, Rizvi AZ, Alden PB et al. Outcomes related to antiplatelet or anticoagulation use in patients undergoing carotid endarterectomy. Ann Vasc Surg 2011; 25: 25–31.
42. Burdess A, Nimmo AF, Garden OJ et al. Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia. Ann Surg 2010; 252: 37–42.
43. Eng M, Brock G, Li X et al. Perioperative anticoagulation and antiplatelet therapy in renal transplant: is there an increase in bleeding complication? Clin Transplant 2011; 25: 292–6.
44. Giannarini G, Mogorovich A, Valent F et al. Continuing or discontinuing low-dose aspirin before transrectal prostate biopsy: results of a prospective randomized trial. Urology 2007; 70: 501–5.
45. Halliwell OT, Yadegafar G, Lane C et al. Transrectal ultrasound-guided biopsy of the prostate: aspirin increases the incidence of minor bleeding complications. Clin Radiol 2008; 63: 557–61.
46. Thurston AV, Briant SL. Aspirin and post-prostatectomy haemorrhage. Br J Urol 1993; 71: 574–6.
47. Wierod FS, Frandsen NJ, Jacobsen JD et al. Risk of haemorrhage from transurethral prostatectomy in acetylsalicylic acid and NSAID-treated patients. Scand J Urol Nephrol 1998; 32: 120–2.
48. Nielsen JD, Holm-Nielsen A, Jespersen J et al. The effect of low-dose acetylsalicylic acid on bleeding after transurethral prostatectomy – a prospective, randomized, double-blind, placebo-controlled study. Scand J Urol Nephrol 2000; 34: 194–8.
49. Ala-Opas MY, Gronlund SS. Blood loss in long-term aspirin users undergoing transurethral prostatectomy. Scand J Urol Nephrol 1996; 30: 203–6.
50. Ferraris VA, Swanson E. Aspirin usage and perioperative blood loss in patients undergoing unexpected operations. Surg Gynecol Obstet 1983; 156: 439–42.
51. Ott MM, Eriksson E, Vanderkolk W et al. Antiplatelet and anticoagulation therapies do not increase mortality in the absence of traumatic brain injury. J Trauma 2010; 68: 560–3.
52. Manning BJ, O’Brien N, Aravindan S et al. The effect of aspirin on blood loss and transfusion requirements in patients with femoral neck fractures. Injury 2004; 35: 121–4.
53. Anekstein Y, Tamir E, Halperin N et al. Aspirin therapy and bleeding during proximal femoral fracture surgery. Clin Orthop Relat Res 2004; 418: 205–8.
54. Edmunds I, Avakian Z. Hand surgery on anticoagulated patients: a prospective study of 121 operations. Hand Surg 2010; 15: 109–13.
55. Devereaux PJ, Mrkobrada M, Sessler DI et al. Aspirin in Patients Undergoing Noncardiac Surgery. N Engl J Med 2014; 370 (16): 1494–503.
56. Fleisher LA, Fleischmann KE, Auerbach AD et al. 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery: Executive Summary. Circulation 2014; 130: 2215–45.
57. Ghaffarinejad MH, Fazelifar AF, Shirvani SM et al. The effect of preoperative aspirin use on postoperative bleeding and perioperative myocardial infarction in patients undergoing coronary artery bypass surgery. Cardiol J 2007; 14: 453–7.
58. Srinivasan AK, Grayson AD, Pullan DM et al. Effect of preoperative aspirin use in off-pump coronary artery bypass operations. Ann Thorac Surg 2003; 76: 41–5.
59. Sun JC, Crowther MA, Warkentin TE et al. Should aspirin be discontinued before coronary artery bypass surgery? Circulation 2005; 112: e85–e90.
60. Preisman S, Kogan A, Itzkovsky K et al. Modified thromboelastography evaluation of platelet dysfunction in patients undergoing coronary artery surgery. Eur J Cardiothorac Surg 2010; 37: 1367–74.
61. Gulbins H, Malkoc A, Ennker IC et al. Preoperative Platelet Inhibition with ASA Does Not Influence Postoperative Blood Loss Following Coronary Artery Bypass Grafting. Thorac Cardiovasc Surg 2009; 57 (1): 18–21.
62. Bybee KA, Powell BD, Valeti U et al. Preoperative aspirin therapy is associated with improved postoperative outcomes in patients undergoing coronary artery bypass grafting. Circulation 2005; 112 (Suppl. 1): I-286–I-292.
63. Bélisle S, Hardy JF. Hemorrhage and the use of blood products after adult cardiac operations: myths and realities. Ann Thorac Surg 1996; 62: 1908–17.
64. Vuylsteke A, Oduro A, Cardan E et al. Effects of aspirin in coronary artery bypass grafting. J Cardiothorac Vasc Anaesth 1997; 11: 831–4.
65. Sun JCJ, Whitlock R, Cheng J et al. The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observational studies. Eur Heart J 2008; 29: 1057–71.
66. Hillis DL, Smith PK, Anderson JL et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. Circulation 2011; 124: e652–e735.
67. Weil J, Colin-Jones D, Langman M et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995; 310: 827–30.
68. Chan FK, Ching JY, Hung LC et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005; 352: 238–44.
69. Weisman SM, Graham DY. Evaluation of the Benefits and Risks of Low-Dose Aspirin in the Secondary Prevention of Cardiovascular and Cerebrovascular Events. Arch Intern Med 2002; 162: 2197–202.
70. Savon JJ, Allen ML, DiMarino AJ Jr et al. Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration. Am J Gastroenterol 1995; 90: 581–5.
71. Dammann HG, Burkhardt F, Wolf N. Enteric coating of aspirin signifcantly decreases gastroduodenal mucosal lesions Aliment. Pharmacol Ther 1999; 13 (8): 1109–14.
72. Walker J, Robinson J, Stewart J et al. Does enteric-coated aspirin result in a lower incidence of gastrointestinal complications compared to normal aspirin? Interact Cardiovasc Thorac Surg 2007; 6: 519–22.
73. Моисеев В.С. Польза и риск антитромботических средств в профилактике сердечно-сосудистых заболеваний. Клин. фармакология и терапия. 2008; 17 (3): 19–24. / Moiseev V.S. Pol'za i risk antitromboticheskikh sredstv v profilaktike serdechno-sosudistykh zabolevanii. Klin. farmakologiia i terapiia. 2008; 17 (3): 19–24. [in Russian]
74. Endo H, Sakai E, Higurashi T et al. Differences in the severity of small bowel mucosal injury based on the type of aspirin as evaluated by capsule endoscopy. Dig Liver Dis 2012; 44 (10): 833–8.
75. Баркаган З.С., Момот А.П., Котовщикова Е.Ф. и др. Выбор препаратов и мониторинг эффективности антитромботических средств. В кн.: Острый коронарный синдром: проблемы патогенеза, диагностики, классификации, терапии. Томск, 2001; с. 192–4. / Barkagan Z.S., Momot A.P., Kotovshchikova E.F. i dr. Vybor preparatov i monitoring effektivnosti antitromboticheskikh sredstv. V kn.: Ostryi koronarnyi sindrom: problemy patogeneza, diagnostiki, klassifikatsii, terapii. Tomsk, 2001; s. 192–4. [in Russian]
76. Cox D, Maree AO, Dooley M et al. Effect of Enteric Coating on Antiplatelet Activity of Low-Dose Aspirin in Healthy Volunteers. Stroke 2006; 37: 2153–8.
77. Maree AO, Curtin RJ, Dooley M et al. Platelet Response to Low-Dose Enteric-Coated Aspirin in Patients With Stable Cardiovascular Disease. JACC 2005; 47: 1258–63.
78. Grosser T, Fries S, Lawson JA. Drug Resistance and Pseudoresistance: An Unintended Consequence of Enteric Coating Aspirin. Circulation 2013; 127 (3): 377–85.
79. Bode-Böger SM, Böger RH, Schubert M et al. Effects of very low dose and enteric-coated acetylsalicylic acid on prostacyclin and thromboxane formation and on bleeding time in healthy subjects. Eur J Clin Pharmacol 1998; 54 (9–10): 707–14.
80. Van Hecken A, Juliano ML, Depré M et al. Effects of enteric-coated, low-dose aspirin on parameters of platelet function. Aliment Pharmacol Ther 2002; 16: 1683–8.
81. ISIS-2 (Second International Study Of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 332 (8607): 349–60.
82. Аверков О.В. Ацетилсалициловая кислота как антитромбоцитарное средство: какие лекарственные формы препарата предпочтительны с позиций доказательной медицины? Кардиоваск. терапия и профилактика. 2010; 9 (2): 61–8. / Averkov O.V. Atsetilsalitsilovaia kislota kak antitrombotsitarnoe sredstvo: kakie lekarstvennye formy preparata predpochtitel'ny s pozitsii dokazatel'noi meditsiny? Kardiovask. terapiia i profilaktika. 2010; 9 (2): 61–8. [in Russian]
83. Jacobs EJ, Thun MJ, Bain EB et al. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 2007; 99: 608–15.
84. Ishikawa H, Mutoh M, Suzuki S et al. The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial. Gut 2014; 63 (11): 1755–9.

________________________________________________

1. Roffi M, Patrono C, Collet J-P et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. EHJ 2015. doi: 10.1093/eurheartj/ehv320
2. Mangano DT. Perioperative cardiac morbidity. Anesthesiology 1990; 72: 153–84.
3. Mangano DT. Perioperative cardiovascular morbidity: new developments. Best Pract Res Clin Anaesthesiol 1999; 13 (3): 335–48.
4. Vicenzi MN, Meislitzer T, Heitzinger B et al. Coronary artery stenting and non-cardiac surgery – a prospective outcome study. Br J Anaesth 2006; 96: 686–93.
5. Iakovou I, Schmidt T, Bonizzoni E et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. J Am Med Assoc 2005; 293: 2126–30.
6. Patrono C, Baigent C, Hirsh J et al. Аntiplatelet Drugs. Chest 2008; 133 (6 Suppl.): 199S–233S.
7. Awtry EH, Loscalzo J. Aspirin. Circulation 2000; 101: 1206–18.
8. Jimenez AH, Stubbs ME, Tofler GH et al. Rapidity and duration of platelet suppression by entericcoated aspirin in healthy young men. Am J Cardiol 1992; 69: 258–62.
9. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86.
10. Hall R, Mazer CD. Antiplatelet drugs: a review of their pharmacology and management in the perioperative period. Anesth Analg 2011; 112: 292–318.
11. Collaborative overview of randomised trials of antiplatelet therapy – I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. BMJ 1994; 308: 81–106.
12. Baigent C, Blackwell L, Collins R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849–60.
13. Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). EHJ 2012; 33: 1635–701.
14. Amsterdam EA, Wenger NK, Brindis RG et al. 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes. Circulation 2014; 130: e344–e426.
15. O’Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. Circulation 2013; 127: e362–e425.
16. Fihn SD, Gardin JM, Abrams J et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. JACC 2012; 60 (24): e44–e164.
17. Brott TG, Halperin JL, Abbara S et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease. Circulation 2011; 124: e54–e130.
18. Rooke TW, Hirsch AT, Misra S et al. 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (Updating the 2005 Guideline). Circulation 2011; 124: 2020–45.
19. Burger W, Chemnitius JM, Kneissl GD et al. Low-dose aspirin for secondary cardiovascular prevention – cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation – review and meta-analysis. J Intern Med 2005; 257: 399–414.
20. Palmer JD, Sparrow OC, Iannotti F. Postoperative hematoma: a 5-year survey and identification of avoidable risk factors. Neurosurgery 1994; 35: 1061–4.
21. Oscarsson A, Gupta A, Fredrikson M et al. To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial. Br J Anaesth 2010; 104: 305–12.
22. Kaluza GL, Joseph J, Lee JR et al. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. JACC 2000; 35: 1288–94.
23. Sharma AK, Ajani AE, Hamwi SM et al. Major noncardiac surgery following coronary stenting: when is it safe to operate? Catheter Cardiovasc Interv 2004; 63: 141–5.
24. Biondi-Zoccai GG, Lotrionte M, Agostoni P et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. EHJ 2006; 27: 2667–74.
25. Collet JP, Himbert F, Steg PG. Myocardial infarction after aspirin cessation in stable coronary artery disease patients. Int J Cardiol 2000; 76: 257–8.
26. Collet JP, Montalescot G, Balnchet B et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation 2004; 110: 2361–7.
27. Ferrari E, Benhamou M, Cerboni P et al. Coronary syndromes following aspirin withdrawal, a special risk for late stent thrombosis. JACC 2005; 45: 456–9.
28. Maulaz AB, Bezerra DC, Michel P, Bogousslavsky J. Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch Neurol 2005; 62 (8): 1217–20.
29. Sung JJ, Lau JY, Ching JY et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med 2010; 152: 1–9.
30. Madan GA, Madan SG, Madan G et al. Minor oral surgery without stopping daily low-dose aspirin therapy: a study of 51 patients. J Oral Maxillofac Surg 2005; 63: 1262–5.
31. Chu MB, Turner RB, Kriegel DA. Patients with drug-eluting stents and management of their anticoagulant therapy in cutaneous surgery. J Am Acad Dermatol 2011; 64: 553–8.
32. Alcalay J, Alkalay R. Controversies in perioperative management of blood thinners in dermatologic surgery: continue or discontinue? Dermatol Surg 2004; 30: 1091–4.
33. Cook-Norris RH, Michaels JD, Weaver AL et al. Complications of cutaneous surgery in patients taking clopidogrel-containing anticoagulation. J Am Acad Dermatol 2011; 65: 584–91.
34. Douketis JD, Spyropoulos AC, Spencer FA et al. Perioperative Management of Antithrombotic Therapy. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST 2012; 141 (2 Suppl.): e326S–e350S.
35. Manocha D, Singh M, Mehta N et al. Bleeding Risk after Invasive Procedures in Aspirin/NSAID Users: Polypectomy Study in Veterans. Am J Med 2012; 125: 1222–7.
36. Yousfi M, Gostout CJ, Baron TH et al. Postpolypectomy lower gastrointestinal bleeding: potential role of aspirin. Am J Gastroenterol 2004; 99: 1785–9.
37. Hui AJ, Wong RM, Ching JY et al. Risk of colonoscopic polypectomy bleeding with anticoagulants and antiplatelet agents: analysis of 1657 cases. Gastrointest Endosc 2004; 59: 44–8.
38. Anderson MA, Ben-Menachem T, Gan SI et al. Management of antithrombotic agents for endoscopic procedures. Gastrointest Endosc 2009; 70: 1060–70.
39. Lindblad B, Persson NH, Takolander R et al. Does low-dose acetylsalicylic acid prevent stroke after carotid surgery? A double blind, placebo-controlled randomized trial. Stroke 1993; 24: 1125–8.
40. Neilipovitz DT, Bryson GL, Nichol G. The effect of perioperative aspirin therapy in peripheral vascular surgery: a decision analysis. Anesth Analg 2001; 93: 573–80.
41. Rosenbaum A, Rizvi AZ, Alden PB et al. Outcomes related to antiplatelet or anticoagulation use in patients undergoing carotid endarterectomy. Ann Vasc Surg 2011; 25: 25–31.
42. Burdess A, Nimmo AF, Garden OJ et al. Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia. Ann Surg 2010; 252: 37–42.
43. Eng M, Brock G, Li X et al. Perioperative anticoagulation and antiplatelet therapy in renal transplant: is there an increase in bleeding complication? Clin Transplant 2011; 25: 292–6.
44. Giannarini G, Mogorovich A, Valent F et al. Continuing or discontinuing low-dose aspirin before transrectal prostate biopsy: results of a prospective randomized trial. Urology 2007; 70: 501–5.
45. Halliwell OT, Yadegafar G, Lane C et al. Transrectal ultrasound-guided biopsy of the prostate: aspirin increases the incidence of minor bleeding complications. Clin Radiol 2008; 63: 557–61.
46. Thurston AV, Briant SL. Aspirin and post-prostatectomy haemorrhage. Br J Urol 1993; 71: 574–6.
47. Wierod FS, Frandsen NJ, Jacobsen JD et al. Risk of haemorrhage from transurethral prostatectomy in acetylsalicylic acid and NSAID-treated patients. Scand J Urol Nephrol 1998; 32: 120–2.
48. Nielsen JD, Holm-Nielsen A, Jespersen J et al. The effect of low-dose acetylsalicylic acid on bleeding after transurethral prostatectomy – a prospective, randomized, double-blind, placebo-controlled study. Scand J Urol Nephrol 2000; 34: 194–8.
49. Ala-Opas MY, Gronlund SS. Blood loss in long-term aspirin users undergoing transurethral prostatectomy. Scand J Urol Nephrol 1996; 30: 203–6.
50. Ferraris VA, Swanson E. Aspirin usage and perioperative blood loss in patients undergoing unexpected operations. Surg Gynecol Obstet 1983; 156: 439–42.
51. Ott MM, Eriksson E, Vanderkolk W et al. Antiplatelet and anticoagulation therapies do not increase mortality in the absence of traumatic brain injury. J Trauma 2010; 68: 560–3.
52. Manning BJ, O’Brien N, Aravindan S et al. The effect of aspirin on blood loss and transfusion requirements in patients with femoral neck fractures. Injury 2004; 35: 121–4.
53. Anekstein Y, Tamir E, Halperin N et al. Aspirin therapy and bleeding during proximal femoral fracture surgery. Clin Orthop Relat Res 2004; 418: 205–8.
54. Edmunds I, Avakian Z. Hand surgery on anticoagulated patients: a prospective study of 121 operations. Hand Surg 2010; 15: 109–13.
55. Devereaux PJ, Mrkobrada M, Sessler DI et al. Aspirin in Patients Undergoing Noncardiac Surgery. N Engl J Med 2014; 370 (16): 1494–503.
56. Fleisher LA, Fleischmann KE, Auerbach AD et al. 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery: Executive Summary. Circulation 2014; 130: 2215–45.
57. Ghaffarinejad MH, Fazelifar AF, Shirvani SM et al. The effect of preoperative aspirin use on postoperative bleeding and perioperative myocardial infarction in patients undergoing coronary artery bypass surgery. Cardiol J 2007; 14: 453–7.
58. Srinivasan AK, Grayson AD, Pullan DM et al. Effect of preoperative aspirin use in off-pump coronary artery bypass operations. Ann Thorac Surg 2003; 76: 41–5.
59. Sun JC, Crowther MA, Warkentin TE et al. Should aspirin be discontinued before coronary artery bypass surgery? Circulation 2005; 112: e85–e90.
60. Preisman S, Kogan A, Itzkovsky K et al. Modified thromboelastography evaluation of platelet dysfunction in patients undergoing coronary artery surgery. Eur J Cardiothorac Surg 2010; 37: 1367–74.
61. Gulbins H, Malkoc A, Ennker IC et al. Preoperative Platelet Inhibition with ASA Does Not Influence Postoperative Blood Loss Following Coronary Artery Bypass Grafting. Thorac Cardiovasc Surg 2009; 57 (1): 18–21.
62. Bybee KA, Powell BD, Valeti U et al. Preoperative aspirin therapy is associated with improved postoperative outcomes in patients undergoing coronary artery bypass grafting. Circulation 2005; 112 (Suppl. 1): I-286–I-292.
63. Bélisle S, Hardy JF. Hemorrhage and the use of blood products after adult cardiac operations: myths and realities. Ann Thorac Surg 1996; 62: 1908–17.
64. Vuylsteke A, Oduro A, Cardan E et al. Effects of aspirin in coronary artery bypass grafting. J Cardiothorac Vasc Anaesth 1997; 11: 831–4.
65. Sun JCJ, Whitlock R, Cheng J et al. The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observational studies. Eur Heart J 2008; 29: 1057–71.
66. Hillis DL, Smith PK, Anderson JL et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. Circulation 2011; 124: e652–e735.
67. Weil J, Colin-Jones D, Langman M et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995; 310: 827–30.
68. Chan FK, Ching JY, Hung LC et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005; 352: 238–44.
69. Weisman SM, Graham DY. Evaluation of the Benefits and Risks of Low-Dose Aspirin in the Secondary Prevention of Cardiovascular and Cerebrovascular Events. Arch Intern Med 2002; 162: 2197–202.
70. Savon JJ, Allen ML, DiMarino AJ Jr et al. Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration. Am J Gastroenterol 1995; 90: 581–5.
71. Dammann HG, Burkhardt F, Wolf N. Enteric coating of aspirin signifcantly decreases gastroduodenal mucosal lesions Aliment. Pharmacol Ther 1999; 13 (8): 1109–14.
72. Walker J, Robinson J, Stewart J et al. Does enteric-coated aspirin result in a lower incidence of gastrointestinal complications compared to normal aspirin? Interact Cardiovasc Thorac Surg 2007; 6: 519–22.
73. Moiseev V.S. Pol'za i risk antitromboticheskikh sredstv v profilaktike serdechno-sosudistykh zabolevanii. Klin. farmakologiia i terapiia. 2008; 17 (3): 19–24. [in Russian]
74. Endo H, Sakai E, Higurashi T et al. Differences in the severity of small bowel mucosal injury based on the type of aspirin as evaluated by capsule endoscopy. Dig Liver Dis 2012; 44 (10): 833–8.
75. Barkagan Z.S., Momot A.P., Kotovshchikova E.F. i dr. Vybor preparatov i monitoring effektivnosti antitromboticheskikh sredstv. V kn.: Ostryi koronarnyi sindrom: problemy patogeneza, diagnostiki, klassifikatsii, terapii. Tomsk, 2001; s. 192–4. [in Russian]
76. Cox D, Maree AO, Dooley M et al. Effect of Enteric Coating on Antiplatelet Activity of Low-Dose Aspirin in Healthy Volunteers. Stroke 2006; 37: 2153–8.
77. Maree AO, Curtin RJ, Dooley M et al. Platelet Response to Low-Dose Enteric-Coated Aspirin in Patients With Stable Cardiovascular Disease. JACC 2005; 47: 1258–63.
78. Grosser T, Fries S, Lawson JA. Drug Resistance and Pseudoresistance: An Unintended Consequence of Enteric Coating Aspirin. Circulation 2013; 127 (3): 377–85.
79. Bode-Böger SM, Böger RH, Schubert M et al. Effects of very low dose and enteric-coated acetylsalicylic acid on prostacyclin and thromboxane formation and on bleeding time in healthy subjects. Eur J Clin Pharmacol 1998; 54 (9–10): 707–14.
80. Van Hecken A, Juliano ML, Depré M et al. Effects of enteric-coated, low-dose aspirin on parameters of platelet function. Aliment Pharmacol Ther 2002; 16: 1683–8.
81. ISIS-2 (Second International Study Of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 332 (8607): 349–60.
82. Averkov O.V. Atsetilsalitsilovaia kislota kak antitrombotsitarnoe sredstvo: kakie lekarstvennye formy preparata predpochtitel'ny s pozitsii dokazatel'noi meditsiny? Kardiovask. terapiia i profilaktika. 2010; 9 (2): 61–8. [in Russian]
83. Jacobs EJ, Thun MJ, Bain EB et al. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 2007; 99: 608–15.
84. Ishikawa H, Mutoh M, Suzuki S et al. The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial. Gut 2014; 63 (11): 1755–9.

С.С.Алтарев*, О.Л.Барбараш

ФГБНУ НИИ комплексных проблем сердечно-сосудистых заболеваний. 650002, Россия, Кемерово, Сосновый б-р, д. 6
*altarev@inbox.ru

________________________________________________

S.S.Altarev*, O.L.Barbarash

Research Institute for Complex Issues of Cardiovascular Diseases. 650002, Russian Federation, Kemerovo, Sosnovyi b-r, d. 6
*altarev@inbox.ru